HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $62
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Douglas Tsao maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $55 to $62.
HC Wainwright & Co. analyst Douglas Tsao maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $55 to $62.